Lifecore Biomedical (NASDAQ: LFCR) is a contract development and manufacturing organization (CDMO) that develops and manufactures complex sterile injectable pharmaceutical and medical device products. Revenue comes from long-term supply and contract manufacturing agreements under which Lifecore provides hyaluronic acid (HA) raw materials, formulation development, and aseptic filling of finished products in syringes, vials, and cartridges. The company is a fully vertically integrated CDMO with over 40 years of regulatory history with the FDA, EMA, and ANVISA. Customer concentration is high: three customers each exceeded 10% of revenue in the fiscal year ended May 25, 2025, with Alcon at 44%, a second customer at 18%, and a third at 10%. In September 2024, Lifecore installed a new 5-head aseptic isolator filler, expanding stated annual revenue-generating capacity to approximately $300 million. Paul Josephs joined as CEO in May 2024. The company carries an asset-based revolving credit facility with BMO Harris Bank N.A. and a Term Loan Credit Facility, making it debt-dependent rather than cash-rich.

Revenue model

Long-term supply agreements and contract manufacturing agreements for aseptic filling and development services, covering HA raw material supply, technology transfer, formulation development, and finished sterile injectable manufacturing. Revenue is transactional and volume-based under multi-year customer contracts.

Products and services

Hyaluronic acid (HA) in bulk form and as formulated, filled syringes and vials for ophthalmic and orthopedic injectable products. Aseptic filling of sterile injectables in syringes, vials, and cartridges. Development services including analytical method development, formulation development, sterile filtration, process scale-up, stability studies, process validation, and clinical materials production.

Customers and end markets

Pharmaceutical and medical device companies requiring outsourced sterile injectable manufacturing. End markets include ophthalmic and orthopedic applications. Alcon is the largest customer at 44% of revenue (FY ended May 25, 2025) and is also one of the company's primary lenders. Two additional customers accounted for 18% and 10% of revenue respectively in the same period.

Value-chain role

Vertically integrated CDMO positioned from upstream HA raw material production through clinical and commercial-scale aseptic fill-finish manufacturing. Assumes full supply chain responsibilities for customers, including regulatory and quality compliance under cGMP standards.

Geographic exposure

The 10-K references regulatory relationships with FDA, EMA, and ANVISA, indicating customers across the United States, Europe, and Brazil, but the filing does not disclose a specific geographic revenue breakdown.

Source: SEC 10-K, filed 2025-08-07

Industry: Pharmaceutical Preparations Peers: Whole Earth Brands, Inc. Bridgford Foods Corp Tattooed Chef, Inc. Mondelez International Inc Real Good Food Company, Inc. Seneca Foods Corp Vital Farms Inc